• General education about women's access to healthcare benefits under the federal law; issues related to opioid addiction. Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.
• Policies impacting U.S. address to the Covid-19 pandemic, including H.R. 604 Coronavirus Preparedness and Response Supplemental Appropriations Act, Public Law No: 116-123.; H. R . 6201 Families First Coronavirus Response Act, Public Law No: 116-127; and H. R. 748 CARES Act, Public Law No: 116-136; and H.R. 133, Consolidated Appropriations Act, 2021, Public Law No: 116-260.

Duration: November 27, 2017 to January 1, 2021

General Issues: Health Issues, Budget/Appropriations, Medicare/Medicaid

Spending: about $320,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2017: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS), White House Office

Affiliated organizations: Bayer U.S., LLC; Merck & Co., Inc.; Bayer Corporation